FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180
October 29, 2015 10:46 AM EDTUBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.
Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More
Amgen (AMGN) Announces FDA Approval of IMLYGIC
October 27, 2015 4:54 PM EDTAmgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. IMLYGIC is the first oncolytic viral therapy approved by the FDA based on therapeutic benefit demonstrated in a pivotal study.1-3
IMLYGIC is a genetically modified herpes... More
